230 related articles for article (PubMed ID: 16802138)
1. Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: A physiopathologic approach.
García-Berrocal JR; Ibáñez A; Rodríguez A; González-García JA; Verdaguer JM; Trinidad A; Ramírez-Camacho R
Eur Arch Otorhinolaryngol; 2006 Nov; 263(11):977-82. PubMed ID: 16802138
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic intratympanic methylprednisolone injection for treatment of refractory sudden sensorineural hearing loss and one case in pregnancy.
Chen Y; Wen L; Hu P; Qiu J; Lu L; Qiao L
J Otolaryngol Head Neck Surg; 2010 Dec; 39(6):640-5. PubMed ID: 21144358
[TBL] [Abstract][Full Text] [Related]
3. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
Van Wijk F; Staecker H; Keithley E; Lefebvre PP
Audiol Neurootol; 2006; 11(6):357-65. PubMed ID: 16988499
[TBL] [Abstract][Full Text] [Related]
4. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.
Harris JP; Weisman MH; Derebery JM; Espeland MA; Gantz BJ; Gulya AJ; Hammerschlag PE; Hannley M; Hughes GB; Moscicki R; Nelson RA; Niparko JK; Rauch SD; Telian SA; Brookhouser PE
JAMA; 2003 Oct; 290(14):1875-83. PubMed ID: 14532316
[TBL] [Abstract][Full Text] [Related]
5. Transtympanic steroids as a salvage therapy in sudden hearing loss: preliminary results.
Dallan I; Bruschini L; Nacci A; Bruschini P; Traino C; Rognini F; Fattori B
ORL J Otorhinolaryngol Relat Spec; 2006; 68(5):247-52. PubMed ID: 16679810
[TBL] [Abstract][Full Text] [Related]
6. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.
Lobo D; Trinidad A; García-Berrocal JR; Verdaguer JM; Ramírez-Camacho R
Eur Arch Otorhinolaryngol; 2006 Jul; 263(7):622-6. PubMed ID: 16547758
[TBL] [Abstract][Full Text] [Related]
7. [Acute bilateral sensorineural hearing loss caused by immuno-mediated inner ear disease].
Abbate A; Viaggio MB; Piras D; López L; Hubscher O; Nogués M
Medicina (B Aires); 2001; 61(6):860-2. PubMed ID: 11808429
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.
Parnes LS; Sun AH; Freeman DJ
Laryngoscope; 1999 Jul; 109(7 Pt 2):1-17. PubMed ID: 10399889
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated inner ear disease: 10-year experience.
Broughton SS; Meyerhoff WE; Cohen SB
Semin Arthritis Rheum; 2004 Oct; 34(2):544-8. PubMed ID: 15505770
[TBL] [Abstract][Full Text] [Related]
10. l-Thyroxine does not prevent immunemediated sensorineural hearing loss in autoimmune thyroid diseases.
Rodríguez-Valiente A; Álvarez-Montero Ó; Górriz-Gil C; García-Berrocal JR
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(4):229-234. PubMed ID: 30107874
[TBL] [Abstract][Full Text] [Related]
11. Transtympanic steroids for treatment of sudden hearing loss.
Gianoli GJ; Li JC
Otolaryngol Head Neck Surg; 2001 Sep; 125(3):142-6. PubMed ID: 11555744
[TBL] [Abstract][Full Text] [Related]
12. Topical steroid therapy using the Silverstein Microwick in sudden sensorineural hearing loss after failure of conventional treatment.
Van Wijck F; Staecker H; Lefebvre PP
Acta Otolaryngol; 2007 Oct; 127(10):1012-7. PubMed ID: 17851934
[TBL] [Abstract][Full Text] [Related]
13. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial.
Rauch SD; Halpin CF; Antonelli PJ; Babu S; Carey JP; Gantz BJ; Goebel JA; Hammerschlag PE; Harris JP; Isaacson B; Lee D; Linstrom CJ; Parnes LS; Shi H; Slattery WH; Telian SA; Vrabec JT; Reda DJ
JAMA; 2011 May; 305(20):2071-9. PubMed ID: 21610239
[TBL] [Abstract][Full Text] [Related]
14. Targeted topical steroid therapy in sudden sensorineural hearing loss.
Kopke RD; Hoffer ME; Wester D; O'Leary MJ; Jackson RL
Otol Neurotol; 2001 Jul; 22(4):475-9. PubMed ID: 11449103
[TBL] [Abstract][Full Text] [Related]
15. Open trial of methotrexate as treatment for autoimmune hearing loss.
Matteson EL; Fabry DA; Facer GW; Beatty CW; Driscoll CL; Strome SE; McDonald TJ
Arthritis Rheum; 2001 Apr; 45(2):146-50. PubMed ID: 11324778
[TBL] [Abstract][Full Text] [Related]
16. [Auto-immune sensorineural deafness: physiopathology and therapeutic approach].
Hervier B; Bordure P; Masseau A; Calais C; Agard C; Hamidou M
Rev Med Interne; 2010 Mar; 31(3):222-8. PubMed ID: 19233519
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated inner ear disorders.
Moscicki RA
Baillieres Clin Neurol; 1994 Nov; 3(3):547-63. PubMed ID: 7874408
[TBL] [Abstract][Full Text] [Related]
18. Immune-Mediated Inner Ear Disease: Diagnostic and therapeutic approaches.
Penêda JF; Lima NB; Monteiro F; Silva JV; Gama R; Condé A
Acta Otorrinolaringol Esp (Engl Ed); 2019; 70(2):97-104. PubMed ID: 29525415
[TBL] [Abstract][Full Text] [Related]
19. Use of methotrexate for autoimmune hearing loss.
Matteson EL; Tirzaman O; Facer GW; Fabry DA; Kasperbauer J; Beatty CW; McDonald TJ
Ann Otol Rhinol Laryngol; 2000 Aug; 109(8 Pt 1):710-4. PubMed ID: 10961801
[TBL] [Abstract][Full Text] [Related]
20. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss.
Herr BD; Marzo SJ
Otolaryngol Head Neck Surg; 2005 Apr; 132(4):527-31. PubMed ID: 15806039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
